Abstract
BackgroundIt is known that Tocilizumab (TCZ) is effective option in systemic Juvenile idiopathic arthritis (sJIA). NNZ had “off label” status for children in Russia till December 2011, but with Ethics...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have